The "Scanvir" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a "test, treat and cure" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.
Adult 18 and over
Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
Patient not opposed to research
Age under 18
Patient opposed to research
drug users and vulnerable populations in non-conventional structures
Other
Prospective
Not listed
Evaluate the acceptability and the feasibility of simultaneous screening for viral hepatitis B, C and HIV among drug users and vulnerable populations in non-conventional structures using a triple method with RTD and FibroScan® and GeneXpert®.
Feasibility will be assessed by the number of days and the number of participants in all sessions. the acceptability of TROD and/or Fibroscan will be assessed by the number and proportion of double screenings (TROD and/or Fibroscan) performed in relation to the number of screenings offered
Reinforce screening for hepatitis B (HBV), hepatitis Delta (HDV) and HIV,
Number and proportion of patients who accepted immediate consultation with the hepatologist,
Reinforce education to prevent the risk of viral transmission,
Number and proportion of patients who accepted risk prevention education by the nurse
Encourage HBV vaccination,
Number of HBV vaccinations offered,
Evaluate the feasibility of PCR (GeneXpert/Buvard),
Number of GeneXpert PCRs performed, Number of PCRs performed on blotting paper,
Click on the lead sponsor to view all of their trials.
